Alto Neuroscience (Alto Neuroscience) ROCE % : -67.74% (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alto Neuroscience's annualized ROCE % for the quarter that ended in Dec. 2023 was -67.74%.

Alto Neuroscience ROCE % Historical Data

The historical data trend for Alto Neuroscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience ROCE % Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-33.66

-76.68

-55.32

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
ROCE %	-	-	-67.58	-	-67.74

Alto Neuroscience ROCE % Calculation

Alto Neuroscience's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-34.935	/	( ( (50.854 - 5.56)	+	(86.628 - 5.61) )	/ 2 )
	=	-34.935	/	( (45.294	+	81.018)	/ 2 )
	=	-34.935	/	63.156
	=	-55.32 %

Alto Neuroscience's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-43.444	/	( ( (53.237 - 5.98)	+	(86.628 - 5.61) )	/ 2 )
	=	-43.444	/	( ( 47.257	+	81.018 )	/ 2 )
	=	-43.444	/	64.1375
	=	-67.74 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Alto Neuroscience (NYSE:ANRO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alto Neuroscience ROCE % Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024